Literature DB >> 24313838

Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.

M Zibetti1, A Merola, C A Artusi, L Rizzi, S Angrisano, D Reggio, C De Angelis, M Rizzone, L Lopiano.   

Abstract

BACKGROUND AND
PURPOSE: Levodopa/carbidopa intestinal gel (LCIG) infusion is nowadays becoming an established therapeutic option for advanced Parkinson's disease (PD) patients with fluctuating symptoms unresponsive to conventional oral treatment. As the implementation of LCIG therapy is increasing, there is a need for safety and efficacy data from current clinical practice.
METHODS: All PD patients treated with LCIG at our centre over a 7-year period were analysed to determine the duration of treatment, retention rate, reasons for discontinuation, LCIG efficacy in motor complications, modifications of concomitant therapy and adverse events.
RESULTS: Of the 59 patients, seven subjects (12%) died of causes unrelated to LCIG infusion and 11 patients (19%) discontinued therapy prior to the cut-off date. Duodopa improved motor complications and over 90% of patients reported an improvement in their quality of life, autonomy and clinical global status. The most common adverse events were dislocation and kinking of the intestinal tube.
CONCLUSIONS: LCIG infusion is effective for the long-term treatment of advanced PD patients and exerts a positive and clinically significant effect on motor complications with a relatively low dropout rate.
© 2013 The Author(s) European Journal of Neurology © 2013 EFNS.

Entities:  

Keywords:  Parkinson's disease; duodopa; levodopa/carbidopa intestinal gel infusion; long-term follow-up

Mesh:

Substances:

Year:  2013        PMID: 24313838     DOI: 10.1111/ene.12309

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  36 in total

1.  Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson's disease and their caregivers.

Authors:  Rosella Ciurleo; Francesco Corallo; Lilla Bonanno; Viviana Lo Buono; Giuseppe Di Lorenzo; Roberta Versaci; Cettina Allone; Rosanna Palmeri; Placido Bramanti; Silvia Marino
Journal:  J Neurol       Date:  2018-06-27       Impact factor: 4.849

2.  Enteral Levodopa Therapy in Advanced Parkinson's Disease with Gastroparesis.

Authors:  Anil Venkitachalam; Adriana Lazarescu; Oksana Suchowersky
Journal:  Mov Disord Clin Pract       Date:  2015-06-04

Review 3.  Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.

Authors:  Johan Virhammar; Dag Nyholm
Journal:  Ther Adv Neurol Disord       Date:  2016-12-01       Impact factor: 6.570

Review 4.  An update on the diagnosis and treatment of Parkinson disease.

Authors:  Philippe Rizek; Niraj Kumar; Mandar S Jog
Journal:  CMAJ       Date:  2016-05-24       Impact factor: 8.262

Review 5.  Novel Levodopa Formulations for Parkinson's Disease.

Authors:  Maria Eliza Freitas; Marta Ruiz-Lopez; Susan H Fox
Journal:  CNS Drugs       Date:  2016-11       Impact factor: 5.749

Review 6.  Advanced stages of PD: interventional therapies and related patient-centered care.

Authors:  Rejko Krüger; Rüdiger Hilker; Christian Winkler; Michael Lorrain; Matthias Hahne; Christoph Redecker; Paul Lingor; Wolfgang H Jost
Journal:  J Neural Transm (Vienna)       Date:  2015-07-03       Impact factor: 3.575

Review 7.  Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.

Authors:  Karin Wirdefeldt; Per Odin; Dag Nyholm
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

8.  Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion.

Authors:  Tommaso Martino; Donato Melchionda; Paolo Tonti; Vincenzo De Francesco; Alessandra Lalla; Luigi Maria Specchio; Carlo Avolio
Journal:  J Neural Transm (Vienna)       Date:  2016-09-10       Impact factor: 3.575

9.  Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-11

Review 10.  Non-oral Continuous Drug Delivery Techniques in Parkinson's Disease: For Whom, When, and How?

Authors:  Jonathan Timpka; Tove Henriksen; Per Odin
Journal:  Mov Disord Clin Pract       Date:  2016-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.